Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
66 hedge funds and large institutions have $110M invested in Soleno Therapeutics in 2020 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 13 closing their positions.
334% more call options, than puts
Call options by funds: $395K | Put options by funds: $91K
136% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 11
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
15% more capital invested
Capital invested by funds: $96.1M → $110M (+$14.2M)
3% more funds holding
Funds holding: 64 → 66 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.16% less ownership
Funds ownership: 3.85% → 3.69% (-0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.24M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$1.36M |
| 3 |
Two Sigma Advisers
New York
|
+$1.34M |
| 4 |
Two Sigma Investments
New York
|
+$1.06M |
| 5 |
Goldman Sachs
New York
|
+$583K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.74M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.67M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.36M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$827K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$748K |
SLNO Hedge Fund Activity: Q3 2020 in Review
66 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2020, worth a combined $110M — up 15% from $96.1M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new SLNO positions and 13 closed out — a net gain of 2 holders — while 26 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $2.24M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.74M sold.
- 66 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2020, up from 64 in Q2 2020.
- Funds reported $110M of Soleno Therapeutics stock for Q3 2020, up 15% quarter-over-quarter.
- 15 funds opened new Soleno Therapeutics positions in Q3 2020 and 13 closed out, a net change of +2 holders.
- The largest Soleno Therapeutics buyer in Q3 2020 was BlackRock, an estimated $2.24M added.
- The largest Soleno Therapeutics seller in Q3 2020 was Sphera Funds Management, an estimated $2.74M sold.
Based on aggregated 13F filings for Q3 2020.